文献速递免疫规划传染病防控与疫情报告

口服脊灰疫苗停用后三种灭活脊灰疫苗免疫程序免疫原性随机对照试验

Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial.
PubMed 文献 · Vaccine · 2021-09-02

在孟加拉国达卡开展开放标签IV期随机对照试验,987名6周龄健康婴儿随机分组,比较三种两剂次IPV程序的免疫原性。10月龄时,14周与9月龄组对三型脊灰病毒累积免疫应答≥99%,显著高于6周与14周龄组的77-81%;6周与9月龄组为98-99%,亦显著高于6周与14周龄组但与14周与9月龄组无差异。结果支持现行SAGE建议,并提示两剂次全剂量IPV可早至6周龄开始。

要点

  • 14周与9月龄两剂IPV对三型脊灰累积免疫应答≥99%。
  • 6周与14周龄两剂IPV累积免疫应答仅77-81%,显著较低。
  • 6周与9月龄两剂IPV应答98-99%,不劣于14周与9月龄程序。

核心结论

  • 结果支持口服脊灰疫苗停用后SAGE现行IPV建议,并提示两剂次全剂量IPV可早至6周龄开始。

研究设计与样本

  • 在孟加拉国达卡两个站点开展开放标签、IV期、随机对照试验。
  • 987名6周龄健康婴儿随机分入含OPV与不含OPV的五组,本文呈现三个IPV-only组:C组14周与9月龄、D组6周与9月龄、E组6周与14周龄。
  • 936名婴儿纳入意向性治疗分析,主要结局为10月龄时三型脊灰病毒血清阳转或抗体滴度四倍升高及抗体滴度中位数倒数。

主要发现

  • 10月龄时C组对三型脊灰病毒累积免疫应答≥99%,显著高于E组的77-81%。
  • D组累积免疫应答为98-99%,显著高于E组(P值<0.0001),但与C组无差异。

关键数值与推荐

  • 免疫应答定义为血清阴性(<1:8)转为血清阳性(≥1:8)或抗体滴度四倍升高。
  • SAGE现行建议为≥14周龄开始两剂次IPV程序,目标至少90%免疫应答。

临床怎么用

  • OPV停用后可采用两剂次全剂量IPV程序,起始年龄可考虑早至6周龄。
  • 若采用6周与14周龄程序,需注意其累积免疫应答显著低于14周与9月龄或6周与9月龄程序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare the immunogenicity of three different two-dose IPV schedules started before or at 14-weeks of age. METHODS: We conducted a randomized, controlled, open-label, inequality trial at two sites in Dhaka, Bangladesh. Healthy infants at 6-weeks of age were randomized into one of five arms to receive two-dose IPV schedules at different ages with and without OPV. The three IPV-only arms are presented: Arm C received IPV at 14-weeks and 9-months; Arm D received IPV at 6-weeks and 9-months; and Arm E received IPV at 6 and 14-weeks. The primary outcome was immune response defined as seroconversion from seronegative (<1:8) to seropositive (≥1:8) after vaccination, or a four-fold rise in antibody titers and median reciprocal antibody titers to all three poliovirus types measured at 10-months of age. FINDINGS: Of the 987 children randomized to Arms C, D, and E, 936 were included in the intention-to-treat analysis. At 10-months, participants in Arm C (IPV at 14-weeks and 9-months) had ≥99% cumulative immune response to all three poliovirus types which was significantly higher than the 77-81% observed in Arm E (IPV at 6 and 14-weeks). Participants in Arm D (IPV at 6-weeks and 9-months) had cumulative immune responses of 98-99% which was significantly higher than that of Arm E (p value < 0.0001) but not different from Arm C. INTERPRETATION: Results support current SAGE recommendations for IPV following OPV cessation and provide evidence that the schedule of two full IPV doses could begin as early as 6-weeks.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zaman K, Kovacs SD, Vanderende K, et al. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. Vaccine. 2021. PMID: 34481702. doi:10.1016/j.vaccine.2021.08.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。